PerkinElmer — A Sign Of What's To Come For Diagnostics

Law360, New York (February 28, 2013, 10:32 AM EST) -- Patent practitioners today are aware of the potential impact that a patentability inquiry under 35 U.S.C. § 101 may have on determining whether an invention is eligible for patent protection, including for those innovations within the biopharmaceutical arts. Providing the latest guidance on the patentability of diagnostic method patents, particularly as used in the growing field of personalized medicine, is the U.S. Supreme Court’s March 2012 decision in Mayo Collaborative Svcs. v. Prometheus Labs. Inc.[1] and the Federal Circuit’s August 2012 decision in Ass’n for Molecular...
To view the full article, register now.